LyGenesis

LyGenesis is a clinical-stage biotechnology company whose cell therapy uses the patient's lymph nodes as bioreactors to regenerate functional ectopic organs. LyGenesis’ lead allogeneic cell therapy program is currently in Phase 2a clinical trials for patients with end-stage liver disease. LyGenesis' drug development pipeline includes cell therapies capable of generating ectopic thymus (for aging and various other potential indications), pancreas (for Type 1 diabetes), and kidney (for end-stage renal disease).